

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CD7 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse CD7 is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Kidney embryonic cell line HEK293-derived recombinant human CD7 Ala26-Pro180 Accession # P09564
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

CyTOF-ready	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.
Flow Cytometry	Optimal dilution of this antibody should be experimentally determined.
Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

CD7 (Cluster of Differentiation Antigen 7; also Leu-9, TP41 and GP40) is a 40-44 kDa member of the Ig-superfamily of proteins. It shows restricted expression, being found on fetal thymocytes, CD34⁺ myeloid and lymphoid progenitor cells, memory CLA- CD45RA⁺ T cells, and CD56⁺ IFN-γ secreting NK cells. CD7 binds to both SECTM1/K12 and galectin-1, and when bound to the latter, initiates complex formation with CD43 in cis. Activation of CD7 may result in either cell proliferation or apoptosis, suggesting a context-dependent signaling mechanism. Mature human CD7 is a 215 amino acid (aa) type I transmembrane glycoprotein. It contains a 155 aa extracellular region (aa 26-180) that shows one V-type Ig-like domain (aa 26-130), and a 39 aa C-terminal cytoplasmic domain. There is one potential alternative splice variant that contains a 79 aa substitution for aa 133-240. Over aa 26-180, human CD7 shares only 43% aa sequence identity with mouse CD7.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.